Quantcast

Industry news that matters to you.  Learn more

Biognosys Announces a Technological Breakthrough in the Development of Its Next-Generation Proteomics Workflow

Biognosys AG announced today a breakthrough in the development of its next generation proteomics technology that helps scientists to understand complex biological processes. For the first time, Biognosys’ data-independent acquisition (DIA) mass spectrometry workflow has identified and quantified more peptides than sequentially possible with data dependent acquisition (DDA) on a Thermo Scientific™ Q Exactive™ HF. The DIA method now provides a clear path to the ultimate life science community goal – to quantify every protein, the complete proteome, in a biological sample of interest. The results of the study have recently been published in the journal Molecular and Cellular Proteomics.

Induced Pluripotent Stem Cells: Proteomics Test

Stem cells have the ability to continue dividing and renewing for long periods of up to a year or more and transform from their unspecialised structures into specialised cell types such as heart muscle cells or nerve cells. It was news of these properties that created such as buzz in recent years, with the possibility of generating new tissue to replace damaged or unhealthy tissue in the human body.

New Mass Spectrometric Immunoassay Consumables Enable Large Biomolecule Analysis

Scientists at the forefront of proteomics research can achieve exceptional accuracy and speed using an expanded family of affinity-based consumables for large molecule bioanalysis. The new functionalized pipette tips feature proprietary microcolumn technology designed to enable enhanced, reproducible target purification and reduce complexity in biological samples prior to liquid chromatography-mass spectrometry (LC-MS) protocols.

Bruker Announces Powerful New Mass Spectrometry Systems and Solutions for Life-Science Research, Clinical Research, Biopharma and Applied Markets

At the 62nd ASMS Conference on Mass Spectrometry and Allied Topics recently, Bruker Corporation (NASDAQ:BRKR) announced mass spectrometry-based product introductions for life-science research and proteomics, for clinical research, for pharma/biopharma/CRO customers, as well as for applied and industrial markets. The new systems and solutions are designed to deliver confident analyses with significantly enhanced performance, productivity and versatility.

Industry-Academic Collaboration Targets Major Proteomics Quantitation Advances using Proteome Sciences’ proprietary TMT Technology

Scientists working to discover protein-based biomedical breakthroughs are constrained by the time and cost required to identify and quantify large numbers of proteins. Thermo Fisher Scientific and researchers at Harvard Medical School have teamed up to develop promising new ways to perform protein quantitation on a much larger scale than currently possible, with the goal of accelerating discovery of effective therapies.